• New York, NY
  • United States
  • Blog Posts (90)
  • Discussions
  • Events
  • Groups
  • Photos
  • Photo Albums
  • Videos

zmc111's Page

Zmc111's Blog

Research Trends in Anti-tumor Antibody Drugs-Section Two

Posted on August 17, 2019 at 6:03am 0 Comments

3. Antibody and drug conjugate

Antibody drug conjugates (ADCs) such as SGN-35 and T-DM1 have been clinically successful, and new technologies can facilitate the development of ADCs. ADC research needs to focus on the optimization of antibodies, drugs and linkers to get better ADC drugs.

(1) Antibody and antigen: 1. The target antigen is highly selective, highly expressed in tumors, and not expressed or underexpressed in normal tissues;2. Antigen has good structural…


The importance of IVD software

Posted on August 15, 2019 at 6:19am 0 Comments

The user experience of the IVD instrument is largely determined by the software. In addition to user operating interface, the accuracy of the instrument drip and the movement of the internal components of the instrument are controlled by software.


In addition to instrument control, the diagnostic itself can also use big data and artificial intelligence through software, which is also known as IVD+.

At present, most IVD instruments or reagents are used to…


Five recent research progresses about bispecific antibodies

Posted on August 14, 2019 at 7:21am 0 Comments

  1. Bridging cells (in-transbinding)—bridging cell method

The most commonly used bridging cells are bridging effector T cells and tumor cells, also known as T cell-engaging bsAb (bsTCE). In addition, NK cells, stem cells, and tumor cells etc. are also used. bsTCE directly couples T cells and tumor cells to form immune synapses, activates in TCR, releases granzymes and perforin, and finally lyses tumor cells.

BsTCEs bind to CD3ε in the CD3ε-TCR…


Applications of bispecific antibodies beyond tumors

Posted on August 13, 2019 at 7:25am 0 Comments

As more and more people begin to focus on bispecific antibodies, more companies and research institutes are conducting related studies. In the development of antibody drug compounds, bispecific antibodies have now accounted for about 20% of the share. Among them, about 68% of the drug candidates are concentrated in the tumor field, and about 50% of which are targeting on CD3.

Figure 1. A structure demonstration of bispecific antibodies (Bsab)

Two products are…


Comment Wall

You need to be a member of King Cameran Foundation to add comments!

Join King Cameran Foundation

  • No comments yet!

© 2020   Created by William Jones.   Powered by

Badges  |  Report an Issue  |  Terms of Service